Avalo Therapeutics has initiated the Phase 2 LOTUS trial evaluating AVTX-009, an anti-IL-1β monoclonal antibody, in approximately 180 adults with hidradenitis suppurativa, with topline data expected in 2026.
Avalo Therapeutics has appointed Jennifer Riley as Chief Strategy Officer, effective January 1, 2025, to lead corporate strategy and product pipeline planning.